SG11201908729UA - Phenyl derivatives as pge2 receptor modulators - Google Patents

Phenyl derivatives as pge2 receptor modulators

Info

Publication number
SG11201908729UA
SG11201908729UA SG11201908729UA SG11201908729UA SG 11201908729U A SG11201908729U A SG 11201908729UA SG 11201908729U A SG11201908729U A SG 11201908729UA SG 11201908729U A SG11201908729U A SG 11201908729UA
Authority
SG
Singapore
Prior art keywords
pharmaceuticals
idorsia
allschwil
hegenheimermattweg
international
Prior art date
Application number
Other languages
English (en)
Inventor
Christoph Boss
Olivier Corminboeuf
Heinz Fretz
Isabelle Lyothier
Davide Pozzi
Sylvia Richard-Bildstein
Hervé Siendt
Thierry Sifferlen
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of SG11201908729UA publication Critical patent/SG11201908729UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
SG11201908729U 2017-05-18 2018-05-17 Phenyl derivatives as pge2 receptor modulators SG11201908729UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2017062031 2017-05-18
PCT/EP2018/062862 WO2018210994A1 (en) 2017-05-18 2018-05-17 Phenyl derivatives as pge2 receptor modulators

Publications (1)

Publication Number Publication Date
SG11201908729UA true SG11201908729UA (en) 2019-10-30

Family

ID=62186480

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908729U SG11201908729UA (en) 2017-05-18 2018-05-17 Phenyl derivatives as pge2 receptor modulators

Country Status (32)

Country Link
US (1) US11712438B2 (zh)
EP (1) EP3625222B1 (zh)
JP (1) JP7159214B2 (zh)
KR (1) KR102632028B1 (zh)
CN (1) CN110612296A (zh)
AR (1) AR111941A1 (zh)
AU (1) AU2018269666B2 (zh)
BR (1) BR112019024109A2 (zh)
CA (1) CA3060597A1 (zh)
CL (1) CL2019003275A1 (zh)
CO (1) CO2019010578A2 (zh)
CR (1) CR20190559A (zh)
CY (1) CY1124608T1 (zh)
DK (1) DK3625222T3 (zh)
EA (1) EA201992676A1 (zh)
ES (1) ES2893452T3 (zh)
HR (1) HRP20211533T1 (zh)
HU (1) HUE056080T2 (zh)
IL (1) IL270623B2 (zh)
LT (1) LT3625222T (zh)
MA (1) MA49126B1 (zh)
MX (1) MX2019013718A (zh)
PE (1) PE20191814A1 (zh)
PH (1) PH12019502563A1 (zh)
PL (1) PL3625222T3 (zh)
PT (1) PT3625222T (zh)
RS (1) RS62440B1 (zh)
SG (1) SG11201908729UA (zh)
SI (1) SI3625222T1 (zh)
TW (1) TWI765041B (zh)
UA (1) UA125123C2 (zh)
WO (1) WO2018210994A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
US11446298B2 (en) 2017-05-18 2022-09-20 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
RS62398B1 (sr) 2017-05-18 2021-10-29 Idorsia Pharmaceuticals Ltd Derivati pirimidina kao modulatori receptora pge2
CN110621671A (zh) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物
JP2021510153A (ja) 2018-01-05 2021-04-15 アイカーン スクール オブ メディシン アット マウント サイナイ 膵臓ベータ細胞の増殖を増加させる方法、治療方法、および組成物
WO2019183245A1 (en) 2018-03-20 2019-09-26 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
JP2022515650A (ja) * 2018-12-31 2022-02-21 アイカーン スクール オブ メディシン アット マウント サイナイ キナーゼ阻害剤化合物及び組成物ならびに使用方法
EP4245301A1 (en) 2020-11-13 2023-09-20 ONO Pharmaceutical Co., Ltd. Cancer treatment by combined use of ep4 antagonist and immune checkpoint inhibitor

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948786A (en) 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
ATE395058T1 (de) 2000-03-24 2008-05-15 Asterand Uk Ltd Verwendung von prostanoid-ep4-rezeptor- antagonisten zur behandlung von kopfschmerzen und nachweisverfahren für solche antagonisten
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
GB0031302D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives
GB0031295D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
CA2482382A1 (en) 2002-04-12 2003-10-23 Pfizer Inc. Pyrazole compounds as anti-inflammatory and analgesic agents
EP1494667A1 (en) 2002-04-12 2005-01-12 Pfizer Japan Inc. Imidazole compounds as anti-inflammatory and analgesic agents
CA2485485A1 (en) 2002-05-23 2003-12-04 Theratechnologies Inc. Antagonistic peptides of prostaglandin e2 receptor subtype ep4
DK1603893T3 (da) 2003-01-29 2008-09-08 Asterand Uk Ltd EP4 -Receptorantagonister
US20050153992A1 (en) 2003-08-26 2005-07-14 Teijin Pharma Limited Pyrrolopyrimidine thion derivatives
AP2006003534A0 (en) 2003-09-03 2006-04-30 Pfizer Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists.
US8084457B2 (en) 2003-09-15 2011-12-27 Lead Discovery Center Gmbh Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
BRPI0510666A (pt) 2004-05-04 2007-12-04 Pfizer compostos de amida de arila ou heteroarila de metila substituìda, composições farmacêuticas compreendendo os mesmos, uso e combinação
CN1950334A (zh) 2004-05-04 2007-04-18 辉瑞有限公司 邻位取代的芳基或杂芳基酰胺化合物
HN2005000795A (es) 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
JP5289046B2 (ja) 2005-05-19 2013-09-11 メルク カナダ インコーポレイテッド Ｅｐ４アンタゴニストとしてのキノリン誘導体
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
AR060403A1 (es) 2006-04-12 2008-06-11 Sanofi Aventis Compuestos de amino- pirimidina 2,6- sustituidos -4- monosustituidos como antagonistas del receptor de prostaglandina d2
WO2007121578A1 (en) 2006-04-24 2007-11-01 Merck Frosst Canada Ltd. Indole amide derivatives as ep4 receptor antagonists
AU2007260529B2 (en) 2006-06-12 2012-04-19 Merck Canada Inc. Indoline amide derivatives as EP4 receptor ligands
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
EP2044056B1 (en) 2006-07-14 2012-08-22 Novartis AG Pyrimidine derivatives as alk-5 inhibitors
JP5259592B2 (ja) 2006-08-11 2013-08-07 メルク カナダ インコーポレイテッド Ｅｐ４受容体リガンドとしてのチオフェンカルボキサミド誘導体
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
CA2679175C (en) 2007-02-26 2015-01-13 Merck Frosst Canada Ltd. Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists
CN101641325A (zh) 2007-03-26 2010-02-03 安斯泰来制药株式会社 鸟氨酸衍生物
JP2010522218A (ja) 2007-03-26 2010-07-01 メルク フロスト カナダ リミテツド Ｅｐ４受容体アンタゴニストとしてのナフタレン及びキノリンスルホニル尿素誘導体
EP2014657A1 (de) 2007-06-21 2009-01-14 Bayer Schering Pharma Aktiengesellschaft Diaminopyrimidine als Modulatoren des EP2-Rezeptors
CA2692265A1 (en) 2007-07-03 2009-01-08 Astellas Pharma Inc. Amide compounds
WO2009047359A1 (en) 2007-10-12 2009-04-16 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
CA2714743C (en) 2008-02-19 2017-01-17 Janssen Pharmaceutica N.V. Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase
JP5375824B2 (ja) 2008-05-14 2013-12-25 アステラス製薬株式会社 アミド化合物
US20130225528A1 (en) 2008-05-21 2013-08-29 Ariad Pharmaceuticals, Inc. Phosphorus Derivatives as Kinase Inhibitors
CN102149384B (zh) 2008-08-14 2014-08-20 南京奥昭生物科技有限公司 作为ep4受体拮抗剂的杂环酰胺衍生物
CN102164942B (zh) 2008-09-19 2017-02-15 生物科技研究有限公司 三萜系化合物及其使用的方法
CN102224154A (zh) 2008-09-25 2011-10-19 默克弗罗斯特加拿大有限公司 作为EP4受体拮抗剂的β-咔啉磺酰脲衍生物
WO2011022348A1 (en) 2009-08-18 2011-02-24 Janssen Pharmaceutica Nv Ethylene diamine modulators of fatty acid amide hydrolase
CN102711757A (zh) 2009-11-23 2012-10-03 莱西肯医药有限公司 用于治疗肠易激综合征的方法和分析法
EP2571867B1 (en) 2010-05-21 2015-11-04 Noviga Research AB Novel pyrimidine derivatives
PT2619182T (pt) 2010-09-21 2017-01-17 Eisai R&D Man Co Ltd Composição farmacêutica
WO2012043634A1 (ja) 2010-09-29 2012-04-05 株式会社エヌビィー健康研究所 ヒトプロスタグランジンｅ２受容体ｅｐ４に対する抗体
WO2012066065A1 (en) 2010-11-17 2012-05-24 Novartis Ag Phenyl-heteroaryl amine compounds and their uses
AU2011331161A1 (en) 2010-11-17 2013-05-02 Novartis Ag 3-(aminoaryl)-pyridine compounds
WO2012076063A1 (en) 2010-12-10 2012-06-14 Rottapharm S.P.A. Pyridine amide derivatives as ep4 receptor antagonists
WO2012103071A2 (en) 2011-01-25 2012-08-02 Eisai R&D Management Co., Ltd. Compounds and compositions
EP2688883B1 (en) 2011-03-24 2016-05-18 Noviga Research AB Pyrimidine derivatives
WO2012149528A1 (en) 2011-04-29 2012-11-01 Exelixis, Inc. Inhibitors of inducible form of 6-phosphofructose-2-kinase
WO2012177618A1 (en) 2011-06-20 2012-12-27 Emory University Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto
US9181279B2 (en) 2011-07-04 2015-11-10 Rottapharm Biotech S.R.L. Cyclic amine derivatives as EP4 receptor antagonists
EP2554662A1 (en) 2011-08-05 2013-02-06 M Maria Pia Cosma Methods of treatment of retinal degeneration diseases
WO2013090552A1 (en) 2011-12-13 2013-06-20 Yale University Compositions and methods for reducing ctl exhaustion
MX371331B (es) * 2012-04-24 2020-01-27 Vertex Pharma Inhibidores de la proteina cinasa dependiente de acido desoxirribonucleico(adn-pk).
AR091429A1 (es) 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina
TWI572597B (zh) 2012-06-29 2017-03-01 美國禮來大藥廠 二甲基－苯甲酸化合物
EP2711364A1 (en) 2012-09-21 2014-03-26 Chemilia AB 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
AU2013353542B2 (en) 2012-11-27 2018-04-05 Thomas Helledays Stiftelse For Medicinsk Forskning Pyrimidine-2,4-diamine derivatives for treatment of cancer
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
EP2765128A1 (en) 2013-02-07 2014-08-13 Almirall, S.A. Substituted benzamides with activity towards EP4 receptors
TW201443004A (zh) 2013-02-15 2014-11-16 Lilly Co Eli 苯氧基乙氧基化合物
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫－１ｈ－異喹啉化合物
JP6393749B2 (ja) 2013-05-30 2018-09-19 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ｃｘｃｒ７受容体調節剤
SI3009426T1 (en) 2013-06-12 2018-06-29 Kaken Pharmaceutical Co., Ltd. 4-alkynyl imidazole derivatives and a drug containing it as an active ingredient
SG11201601225RA (en) 2013-09-04 2016-03-30 Bristol Myers Squibb Co Compounds useful as immunomodulators
AU2014316682B2 (en) 2013-09-06 2018-11-22 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole derivatives as immunomodulators
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
RU2675270C2 (ru) 2013-10-17 2018-12-18 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы и содержащие их фармацевтические композиции
WO2015058031A1 (en) 2013-10-17 2015-04-23 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
MX368178B (es) 2013-12-17 2019-09-23 Lilly Co Eli Compuestos de ácido dimetilbenzoico.
MX2016007566A (es) 2013-12-17 2016-10-03 Lilly Co Eli Derivados de amina ciclica de fenoxietilo y su actividad como moduladores de receptor ep4.
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
TW201623277A (zh) 2014-03-26 2016-07-01 安斯泰來製藥股份有限公司 醯胺化合物
US10052332B2 (en) 2014-04-29 2018-08-21 Emory University Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto
CN110354266A (zh) 2014-05-23 2019-10-22 卫材 R&D 管理有限公司 用于治疗癌症的组合疗法
CN106794181A (zh) 2014-06-04 2017-05-31 托马斯·黑勒戴药物研究基金会 用于治疗炎性和自身免疫性病况的mth1抑制剂
IL274159B2 (en) 2014-06-19 2024-03-01 Ariad Pharma Inc Heteroaryl compounds for kinase inhibition
WO2016021742A1 (en) 2014-08-07 2016-02-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds as ep4 receptor antagonists
TWI739666B (zh) 2015-01-09 2021-09-11 日商小野藥品工業股份有限公司 醫藥組成物
EP3325490B1 (en) 2015-07-23 2019-12-18 Takeda Pharmaceutical Company Limited 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists
EP3362454B1 (en) 2015-10-16 2021-12-08 Eisai R&D Management Co., Ltd. Ep4 antagonists
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
CA3030783A1 (en) 2016-07-13 2018-01-18 Vertex Pharmaceuticals Incorporated Methods, compositions and kits for increasing genome editing efficiency
CN110621671A (zh) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物
KR102650756B1 (ko) 2017-05-18 2024-03-22 이도르시아 파마슈티컬스 리미티드 N-치환된 인돌 유도체
RS62398B1 (sr) 2017-05-18 2021-10-29 Idorsia Pharmaceuticals Ltd Derivati pirimidina kao modulatori receptora pge2
US11446298B2 (en) 2017-05-18 2022-09-20 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives

Also Published As

Publication number Publication date
HUE056080T2 (hu) 2022-01-28
CO2019010578A2 (es) 2019-10-09
CA3060597A1 (en) 2018-11-22
MA49126A (fr) 2020-03-25
ES2893452T3 (es) 2022-02-09
MA49126B1 (fr) 2021-10-29
HRP20211533T1 (hr) 2022-01-07
DK3625222T3 (da) 2021-10-25
JP7159214B2 (ja) 2022-10-24
TW201900175A (zh) 2019-01-01
CL2019003275A1 (es) 2020-05-04
AU2018269666A1 (en) 2020-01-16
KR102632028B1 (ko) 2024-01-31
WO2018210994A1 (en) 2018-11-22
IL270623A (zh) 2019-12-31
TWI765041B (zh) 2022-05-21
PT3625222T (pt) 2021-10-07
EP3625222A1 (en) 2020-03-25
PE20191814A1 (es) 2019-12-27
CY1124608T1 (el) 2022-07-22
PH12019502563A1 (en) 2020-07-20
MX2019013718A (es) 2020-01-30
JP2020520356A (ja) 2020-07-09
RS62440B1 (sr) 2021-11-30
BR112019024109A2 (pt) 2020-06-02
KR20200010352A (ko) 2020-01-30
AU2018269666B2 (en) 2022-02-03
PL3625222T3 (pl) 2021-12-27
EA201992676A1 (ru) 2020-05-06
EP3625222B1 (en) 2021-07-21
UA125123C2 (uk) 2022-01-12
LT3625222T (lt) 2021-11-10
CR20190559A (es) 2020-02-10
SI3625222T1 (sl) 2021-11-30
AR111941A1 (es) 2019-09-04
US11712438B2 (en) 2023-08-01
IL270623B2 (en) 2023-03-01
CN110612296A (zh) 2019-12-24
US20200179383A1 (en) 2020-06-11
IL270623B (en) 2022-11-01

Similar Documents

Publication Publication Date Title
SG11201908729UA (en) Phenyl derivatives as pge2 receptor modulators
SG11201908097YA (en) Pyrimidine derivatives as pge2 receptor modulators
SG11201908660RA (en) N-substituted indole derivatives
SG11201803627XA (en) N-substituted indole derivatives as pge2 receptor modulators
SG11201808678QA (en) Macrocyclic inhibitors of the pd-1/pd-l1 and cd80/pd-l1 protein/protein interactions
SG11201906763RA (en) Pyrrolo [1,2-b] pyridazine derivatives
SG11201903908PA (en) Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201807543YA (en) Hepatitis b antiviral agents
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201408094YA (en) Neprilysin inhibitors
SG11201907544VA (en) Jak inhibitors containing a 4-membered heterocyclic amide
SG11201408261UA (en) Syringe
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201907604UA (en) Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan
SG11201906959RA (en) Aryl hydrocarbon receptor (ahr) modulator compounds
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201901558VA (en) Pth compounds with low peak-to-trough ratios
SG11201810177VA (en) Pet-imaging immunomodulators
SG11201408617PA (en) Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders
SG11201808686VA (en) Synthesis of indazoles
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201900633XA (en) Piperidine cxcr7 receptor modulators